Domestic new drug Kemena can save 5,000 to 9,000 yuan per month

In 2010, Zhejiang Beida Pharmaceutical Co., Ltd., located in Yuhang, successfully developed a new drug that attracted the world’s top five pharmaceutical companies to snap up patents. Eli Lilly and Company in the United States, at the time, hoped to buy the patent for this drug for $250 million. However, considering the symbolism and market prospects of the drug, Beida Pharmaceuticals decided to bring the drug itself to the market.

This new drug is called "Kamia," which is mainly used for the treatment of lung cancer. It ends the import dependence of China's "targeted anticancer drugs." More importantly, this new drug is cheaper and can give cancer every month. Patients save 5,000 to 9,000 yuan.

On August 13th, at the Beijing People’s Congress Hall, at the “Kemena” new drug conference, Minister of Health Chen Hao commented: This major breakthrough is, I think, a major achievement in the people’s livelihood area that is comparable to “two bullets and one star”. breakthrough.

Yesterday, the successful development of "Kemena" Zhejiang Beida Pharmaceuticals Co., Ltd. signed a letter of intent with the Yuhang District Government to create a common platform for the development of biology and medicine research and development in Hangzhou.

The so-called "targeted anti-cancer drugs," the metaphor of the image is: as accurately guided missiles, accurately find the cancer cells and eliminate them without accidentally injuring healthy cells.

The reason seems simple, but before this, there is no domestic pharmaceutical company that has successfully developed this anticancer drug. The use of this drug by domestic cancer patients depends on imports from several pharmaceutical companies in the United States and the United Kingdom.

Jiao Lihua, manager of Zhejiang Beida Pharmaceutical Market, said that the current price of the generic drug Iressa in the international market is 550 yuan per piece and Tarceva 660 yuan per piece. On average, a cancer patient needs to spend between 16,000 and 20,000 yuan per month on imported drugs.

"Kemena" sells for about 400 yuan each, as long as 11,000 yuan per month, can save 5000 to 9,000 yuan.

As it is a new drug, "Kamier" has not been listed in the national essential drug list and cannot be purchased from the market. It must be bought by a doctor in a hospital.

There are 44 biopharmaceutical registered companies in Yuhang District. Last year, 32 enterprises above designated size completed industrial sales value of 6.345 billion yuan, involving innovative drugs, biological vaccines, diagnostic reagents and other fields, and attracted Novartis Switzerland, the United States Eli Lilly, France Saino Philippine three major pharmaceutical giants (all of the world's top 500 companies) invest in Yuhang